We analysed the IPs up to FUM6, to determine their usefulness in monitoring TB evolution and response to treatment, as we could only find one European cohort extending up to the end of treatment [12], and that study only assessed CRP and ESR. This evidence concerns the gene ESR1 and tuberculosis.